The former commissioner pushed a regulatory pathway for rare disease drugs and launched a voucher program for expedited ...
The firm will report more data on the CAR T-cell therapy's durable efficacy later in the year and anticipates completing regulatory submissions in the fourth quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results